PEPTIDE & SOMATROPINLek, a Sandoz company, today opened a new facility for production of state-of-the-art biopharmaceutical active substances. The new investment of USD 3. The new m2 facility will serve as a global supply point masteron enanthate effects Sandoz modified lke. Over the years, Sandoz and its somatorpin company Novartis somatropin lek invested a somatropin lek of EUR 45 million in biopharmaceuticals in Slovenia — a clear demonstration of corporate confidence in our knowledge and expertise. Lek Biopharmaceuticals is somatropin lek only industrial centre for modern, recombinant technology in Slovenia. There are experts working here pharmacists, somatropin lek, biotechnologists, microbiologists, biochemistsof whom more than one quarter have a PhD or Masters Degree. We offer these Slovenian experts the chance to work in their home country for a major global tren 75 company.
Sandoz receives FDA approval for Omnitrope® Pen 10 with liquid cartridge - Lek
Tokyo -- Sandoz today announced the launch of its recombinant human growth hormone somatropin in Japan, the first-ever biosimilar to be approved and launched on the world's second largest pharmaceutical market. For example, he predicted that biosimilars could generate total savings for Germany's statutory health insurance SHI funds of more than EUR 8. However, speaking at the somatropin launch press conference in Tokyo, he stated his view that these savings would only materialize if politicians and other key payors act to establish the right framework conditions for biosimilar competition, and avoid barriers to entry such as the introduction of a reference price system for biosimilars.
Sandoz pioneered the field of biosimilars also known as follow-on biologics with the approval and subsequent launch of Omnitrope in the US and Europe and the launch of Binocrit across Europe. Biosimilars are approved on the basis that they have demonstrated comparable quality, safety and efficacy to the reference product. Omnitrope was the first such product to be made available to patients in both regions and the first ever medicine to be approved in the EU as a biosimilar.
Sandoz today is the only company with three biosimilar medicines marketed in Europe. Sandoz's leading position in the field leverages its extensive experience in biotechnology, including manufacturing activities for other Novartis divisions as well as for third parties. Sandoz specializes in the development, production and marketing of differentiated products, ranging from biosimilars to complex injectables and inhalables. You should not place undue reliance on these statements.
Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that other biosimilar products will be submitted for approval or approved for sale in any market.
In particular, management's expectations regarding these products could be affected by, among other things, unexpected developmental delays, including unexpected clinical or other laboratory data; unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form F on file with the US Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected.
Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Sandoz Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents.
Sandoz has a portfolio of approximately compounds and sells its products in more than countries. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives.
Insight, Analysis and Views ViewPoints: Fate kicking off a new take on allogeneic CARs. The pharmaceutical industry and social media -- who leads, and who follows? Pharma and Social Media: The Leaders and Followers - click here to find out more.